OncoHost

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHosts proprietary platform, PROphet, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700...

Oncohost operates in the Hospitals and health care industry.

Oncohost's revenue is 11m - 100m

Oncohost has 51 - 200 employees.